Date: 2013-07-08
Type of information: IPO
Company: Prosensa (The Netherlands)
Investors:
Amount: $78 million (€60 million)
Funding type: IPO
Planned used: Prosensa intends to use the proceeds from the offering to fund its current Duchenne Muscular Dystrophy (DMD) development portfolio, its early-stage DMD discovery work and DMD-support projects, to fund other non-DMD projects and for working capital and general corporate purposes.
Others:
* On May 28, 2013, Prosensa has announced that it has filed a registration statement on Friday May 24, 2013 on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its ordinary shares. The company intends to raise up to $60 million in an initial public offering. The number of shares to be offered and the price range for the offering have not been determined. J.P. Morgan and Citigroup are acting as joint book-running managers for the offering. Leerink Swann is acting as lead manager and Wedbush PacGrow Life Sciences and KBC Securities are acting as co-managers.
Therapeutic area: Rare diseases - Neuromuscular diseases